The precision medicine developer attracted returning investors Novo, Novartis Venture Fund and Johnson & Johnson Innovation – JJDC for a crossover financing round.

US-based biotherapeutics developer Escape Bio secured $73m in crossover financing on Monday from investors including pharmaceutical firms Novo, Johnson & Johnson and Novartis. The round was led by investment manager Wellington Management and also featured Avidity Partners, Cam Capital, New Leaf Ventures, Rock Springs Capital, Surveyor Capital, Sphera Funds Management, OrbiMed, Osage University Partners (OUP)…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.